Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Who­ev­er is tak­ing Ote­zla off Bris­tol-My­ers Squibb’s hands will have one more rev­enue stream to boast.

The drug — a ris­ing star in Cel­gene’s pipeline that gen­er­at­ed glob­al sales of $1.6 bil­lion last year — is now OK’d to treat oral ul­cers as­so­ci­at­ed with Be­hçet’s dis­ease, a com­mon symp­tom for a rare in­flam­ma­to­ry dis­or­der. This marks the third FDA ap­proval for the PDE4 in­hibitor since 2014, when it was green­light­ed for plaque pso­ri­a­sis and pso­ri­at­ic arthri­tis.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.